<DOC>
	<DOCNO>NCT00114933</DOCNO>
	<brief_summary>Lopinavir/ritonavir monotherapy may maintain virologic suppression patient undetectable six month triple drug antiretroviral therapy . Lopinavir/ritonavir pharmacokinetics might prevent resistance development patient experience virological rebound single-drug simplification .</brief_summary>
	<brief_title>`` OK 2004 Study '' ( Only Kaletra 2004 Study ) : Study Evaluate Suspending Nucleosides From Triple-Drug Therapy HIV Subjects</brief_title>
	<detailed_description>Primary Study Objective : Efficacy durability switch lopinavir/ritonavir single-drug HAART compare maintain therapy base lopinavir/ritonavir two nucleoside Secondary Study Objective ( ) : - Safety ( related drug AEs/SAEs laboratory anomaly G3/4 ) 48 w. - Resistance profile patient sustain virological failure - QOL compare stop nucleoside versus continue therapy - Pharmaco-economic analysis compare treatment cost 2 study arm . - Predicting factor failure stop nucleoside arm Subject Population : 200 patient Study Design : RANDOMIZATION : Patients randomize ( 1:1 ) either continue treatment stop nucleoside follow : - Stopping nucleoside arm : Lopinavir/r alone . - Continuing arm : Lopinavir/r + 2 NRTIs STUDY PROCEDURES : A baseline HIV-RNA , CD4 routine lab collect recent result collect within 4 week prior enter study . Patients follow HIV-RNA ( CD4 ) w1 , w4 , w8 , w16 , w24 , w 36 w48 . After w48 , durability response lopinavir/r single-drug therapy study long-term ( w96 ) . Routine hematology clinical chemistry ( include fast triglyceride cholesterol , total HDL/LDL ratio ) measure w4 , w16 , w24 , w 36 w48 . A central laboratory use HIV-RNA determination archive plasma/cell sample genotype test case rebound . Treatment adherence follow self-patient report questionnaire ( GEEMA study ) All AEs collect suspected relation ( possible probable ) concomitant ARV drug , SAEs , relate , report within 24h .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>HIV patient &gt; 18 year old provide sign date Informed consent . HIV patient receive lopinavir/ritonavir two nucleoside least 4 week . Plasma HIV RNA &lt; 50 cop/ml six month HIV patient stop protease inhibitor due virological failure . HIV patient hepatic renal insufficiency . HIV patient positive serum HBVAg HIV patient require treatment lopinavir/r contraindicate medication . HIV pregnant breastfeed woman . Active drug abuse ( include alcohol recreational drug ) . Exception , cannabis , provide investigator confident patient adherence . Patients Methadone program accept deemed appropriate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>